Details of the Drug Reposition

General Information of This Drug (ID: DM2YTGQ)

Drug Name
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes   DM2YTGQ
Drug Type
CAR T Cell Therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Phase 1/2 [1]
Acute lymphoblastic leukaemia DIS87TGM 2A85 Phase 1/2 [1]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01865617) Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia